Evidence map›Paper›PMID 29695589›Full record

Trial reportNeurology2018

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.

Jeffrey L Cummings, Sharon Cohen, Christopher H van Dyck, Mark Brody, Craig Curtis, William Cho, Michael Ward, Michel Friesenhahn, Christina Rabe, Flavia Brunstein and 7 more

Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Review
  14. Advances in the treatment of Alzheimer's disease.Frontiers in pharmacology · 2026
    Review
  15. Review
  16. Review
  17. Article
  18. Role of Monoclonal Antibodies in Alzheimer's Disease: Successes, Failures, and Future Directions.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  19. Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy.The Journal of pharmacology and experimental therapeutics · 2025
    Review
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jeffrey L CummingsFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany. cumminj@ccf.org.
Sharon CohenFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Christopher H van DyckFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Mark BrodyFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Craig CurtisFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
William ChoFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Michael WardFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Michel FriesenhahnFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Christina RabeFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Flavia BrunsteinFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Angelica QuartinoFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Lee A HonigbergFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Reina N FujiFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
David ClaytonFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Deborah MortensenFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Carole HoFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.
Robert PaulFrom the Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Toronto Memory Program (S.C.), ON, Canada; Alzheimer's Disease Research Unit (C.H.v.D.), Yale University School of Medicine, New Haven, CT; Brain Matters Research Inc (M.B.), Delray Beach, FL; Compass Research, LLC (C.C.), Orlando, FL; Genentech (W.C., M.W., M.F., F.B., A.Q., L.A.H., R.N.F., D.C., D.M., C.H., R.P.), South San Francisco, CA; and Roche Diagnostics (C.R.), Penzberg, Germany.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
6 · The paper itself

Abstract

objectiveTo evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD).

methodsIn this phase 2 trial, 431 patients with mild to moderate AD 50 to 80 years of age were randomized 2:1 (crenezumab:placebo). Patients received low-dose subcutaneous crenezumab 300 mg or placebo every 2 weeks (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks. Primary outcome measures were change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) and Clinical Dementia Rating-Sum of Boxes scores from baseline to week 73.

resultsThe primary and secondary endpoints were not met. In an exploratory post hoc analysis, a reduction in decline on the ADAS-Cog12 was observed in the high-dose group. Separation from the placebo group on the ADAS-Cog12 was greatest in the milder subsets of AD patients and reached statistical significance in the group with Mini-Mental State Examination scores of 22 to 26. In both groups, there was a significant increase in CSF β-amyloid

conclusionsAlthough prespecified criteria for testing treatment effects were not met, these data suggest a potential treatment effect in patients with mild AD treated with high-dose crenezumab. Together with the safety profile for crenezumab, these data support the exploration of crenezumab treatment at even higher doses in patients with early AD. CLINICALTRIALSGOV IDENTIFIER: NCT 01343966. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, for people with AD, crenezumab does not significantly improve cognition or function at 18 months. The study is rated Class II because <80% of enrolled patients completed the study.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDouble-Blind MethodFemaleHumansMaleMiddle AgedNeuropsychological TestsTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, Humanizedcrenezumab

Identifiers

PMID29695589
PMCPMC5962917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.